InVivo Therapeutics (NVIV) announced that that the 9th and 10th subjects have been implanted in its 20-subject Phase 3 clinical trial, INSPIRE, assessing the Neuro-Spinal Scaffold in patients with acute spinal cord injury. The 10th patient died from a stroke several days post-implantation. The cause of death was determined to be unrelated to the Neuro-Spinal Scaffold. The primary endpoint is the proportion of patients who achieve an improvement of at least one AIS grade level at month 6.